Vimarsana
Biggest News Aggregation in the World

Page 4 - Nasdaq Hook News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Hook. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Hook Today - Breaking & Trending Today

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq - Vimarsana News

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq

NEW YORK and VIENNA, Austria, June 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...

HOOKIPA Pharma to Report First Quarter 2023 Financial - Vimarsana News

HOOKIPA Pharma to Report First Quarter 2023 Financial

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...

Susquehanna International Group LLP Raises Position in Hookipa Pharma Inc (NASDAQ:HOOK) - Vimarsana News

Susquehanna International Group LLP Raises Position in Hookipa Pharma Inc (NASDAQ:HOOK)

Susquehanna International Group LLP raised its holdings in shares of Hookipa Pharma Inc (NASDAQ:HOOK – Get Rating) by 99.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,014 shares of the company’s stock after buying an additional 22,450 shares during the […]

Source: wkrb13.com
Hookipa Pharma (NASDAQ:HOOK) Trading Down 1% - Vimarsana News

Hookipa Pharma (NASDAQ:HOOK) Trading Down 1%

Hookipa Pharma Inc (NASDAQ:HOOK – Get Rating) traded down 1% on Wednesday . The company traded as low as $0.72 and last traded at $0.72. 80,573 shares were traded during mid-day trading, a decline of 55% from the average session volume of 178,531 shares. The stock had previously closed at $0.73. Analyst Upgrades and Downgrades […]

HOOKIPA announces positive Phase 1 data and Phase 2 plans - Vimarsana News

HOOKIPA announces positive Phase 1 data and Phase 2 plans

Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector...